Antidepressant-like pharmacological profile of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene: Involvement of serotonergic system

Neuropharmacology

Volumn 59, Issue 3, 2010, Pages 172-179

  Gay, Bibiana M ^a   Prigol, Marina ^a   Stein, André L ^a   Nogueira, Cristina W ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antidepressant like; Forced swimming test; Organoselenium; Selenophene; Serotonergic system; Tail suspension test

Indexed keywords

3 (4 FLUOROPHENYLSELENYL) 2,5 DIPHENYLSELENOPHENE; ANTIDEPRESSANT AGENT; FENCLONINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ONDANSETRON; PAROXETINE; RITANSERIN; SEROTONIN; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; 3-(4-FLUOROPHENYLSELENYL)-2,5-DIPHENYLSELENOPHENE; AMINE OXIDASE (FLAVIN CONTAINING); BENZENE DERIVATIVE; BENZENESELENOL; ORGANOSELENIUM DERIVATIVE; PROTEIN BINDING; SEROTONIN RECEPTOR AFFECTING AGENT; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EXPERIMENTAL TEST; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; SYNAPTOSOME; TAIL SUSPENSION TEST; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CATALEPSY; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; EXPLORATORY BEHAVIOR; IMMOBILIZATION; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; SWIMMING; TIME; ULTRASTRUCTURE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZENE DERIVATIVES; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FREEZING REACTION, CATALEPTIC; HINDLIMB SUSPENSION; MALE; MICE; MONOAMINE OXIDASE; ORGANOSELENIUM COMPOUNDS; PAROXETINE; PROTEIN BINDING; SEROTONIN; SEROTONIN AGENTS; SWIMMING; SYNAPTOSOMES; TIME FACTORS; TRITIUM;

EID: 77954243818     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.05.003     Document Type: Article

References (53)

1. Aghajanian G.K., Sprouse J.S., Sheldon P., Rasmussen K. Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Annals of New York Academy of Sciences 1990, 600:93-103.
2. 1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 2003, 45:1050-1056.
3. Altamura A.C., DellOsso B., Serati M., Ciabatti M., Buoli M. Recent assessments on the neurobiology of major depression: a critical review. Rivista di Psichiatria 2008, 43:185-207.
4. Benton D., Cook R. The impact of selenium supplementation on mood. Biological Psychiatry 1991, 29:1092-1098.
5. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutritional Neuroscience 2001, 5:363-374.
6. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacological Science 1994, 15:220-226.
7. Bockaert J., Claeysen S., Compan V., Dumuis A. 5-HT4 receptors: history, molecular pharmacology and brain functions. Neuropharmacology 2008, 55:922-931.
8. Bourin M., Chenu F., Prica C., Hascoet M. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology 2009, 206:97-107.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
10. Bruning C.A., Prigol M., Roehrs J.U., Nogueira C.W., Zeni G. Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice. Behavioural Brain Research 2008, 205:511-517.
11. Bundgaard C., Larsen F., Jorgensen M., Gabrielsson J. Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. European Journal of Pharmaceutical Sciences 2006, 29:394-404.
12. Eren I., Naziroglu M., Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochemical Research 2007, 32:1188-1195.
13. Evrard A., Malagie I., Laporte A.M., Boni C., Hanoun N., Trillat A.C., Seif I., De Maeyer E., Gardier A., Hamon M., Adrien J. Altered regulation of the 5-HT system in the brain of MAO-A knock-out mice. European Journal of Neuroscience 2002, 15:841-851.
14. Felton T.M., Kang T.B., Hjorth S., Auerbach S.B. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn-Schmiedebergs Archives of Pharmacology 2003, 367:297-305.
15. Finberg J.P., Pacak K., Kopin I.J., Goldstein D.S. Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Naunyn-Schmiedebergs Archives of Pharmacology 1993, 347:500-505.
16. Gray E.G., Whittaker V.P. The isolation of nerve endings from brain: an electron-microcsope study of cell fragments derived by homogenization and centrifugation. Journal of Anatomy 1962, 96:79-87.
17. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., Kap O., Yumru M., Savas H.A., Akyol O. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Archives of Medical Research 2007, 38:247-252.
18. 1A receptor availability in medication naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C] WAY-100635. International Journal of Neuropsychopharmacology 2008, 11:65-76.
19. Hochman S., Garraway S.M., Machacek D.W., Shay B.L. 5-HT receptors and the neuromodulatory control of spinal cord function. Motor Neurobiology of the Spinal Cord 2003, 47-87. CRC Press, Washington. T.C. Cope (Ed.).
20. Kendler K.S., Gardner C.O., Fiske A., Gatz M. Major depression and coronary artery disease in the Swedish Twin registry. Archives of General Paychiatry 2009, 66:857-863.
21. Koe B.K., Weissman A. p-Chlorophenylalanine: a specific depletor of brain serotonin. Journal of Pharmacology and Experimental Therapeutics 1966, 154:499-516.
22. Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochemical Pharmacology 1965, 14:1684.
23. Krishnan K.R. Revisiting monoamine oxidase inhibitors. Journal of Clinical Psychiatry 2007, 68:35-41.
24. Lazure K.E., Lydiatt W.M., Denman D., Burke W.J. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck-Journal for Sciences Specialties Head Neck 2009, 31:888-892.
25. Machado D.G., Kaster M.P., Binfare R.W., Dias M., Santos A.R.S., Pizzolatti M.G., Brighente I.M., Rodrigues A.L.S. Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: evidence for the involvement of the monoaminergic system. Progress in Neuro-psychopharmacology and Biological Psychiatry 2007, 31:421-428.
26. Matsumoto T., Furuta T., Nimura Y., Suzuki O. 3-(p-Hydroxyphenyl) propionic acid as a new fluorogenic reagent for amine oxidase assays. Analytical Biochemistry 1984, 138:133-136.
27. McKenna M.T., Michaud C.M., Murray C.J.L., Marks J.S. Assessing the burden of disease in the United States using disability-adjusted life years. Journal of Preventive Medicine 2005, 28:415-423.
28. Millan M.J. The role of monoamines in the actions of established and " novel" antidepressant agents: a critical review. European Journal of Pharmacology 2004, 500:371-384.
29. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 2006, 110:135-370.
30. Miorelli S.T., Rosa R.M., Moura D.J., Rocha J.C., Lobo L.A.C., Henriques J.A.P., Saffi J. Antioxidant and anti-mutagenic effects of ebselen in yeast and in cultured mammalian V79 cells. Mutagenesis 2008, 23:93-99.
31. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease - epidemiology, biology, and treatment. Archives of General Paychiatry 1998, 55:580-592.
32. Neu P. Correlation of depression with stroke. Pathophysiological mechanisms. Nervenarzt 2009, 80:772.
33. ONeill M.F., Conway M.W. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001, 24:391-398.
34. Ṕez-Pereda M. New drug targets in the signalling pathways activated by antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1010-1016.
35. (2C) receptor occupancy in rat brain. International Journal of Neuropsychopharmacology 1999, 2:95-99.
36. Peyrot M. Depression: a quiet killer by any name. Diabetes Care 2003, 26:2952-2953.
37. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie 1977, 299:327-336.
38. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
39. Porsolt R.D., Chermat R., Lenegre A., Avril I., Janvier S., Steru L. Use of the automated tail suspension test for the primary screening of psychotropic agents. Archives Internationales de Pharmacodynamie et de Therapie 1987, 288:11-30.
40. Posser T., Kaster M.P., Baraúna S.C., Rocha J.B.T., Rodrigues A.L.S., Leal R.B. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. European Journal of Pharmacology 2009, 602:85-91.
41. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356:233-241.
42. Savegnago L., Jesse C.R., Pinto L.G., Rocha J.B.T., Nogueira C.E., Zeni G. Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 3:1261-1269.
43. Savegnago L., Pinto L.G., Jesse C.R., Alves D., Rocha J.B.T., Nogueira C.W., Zeni G. Antinociceptive properties of diphenyl diselenide: evidences for the mechanism of action. European Journal of Pharmacology 2007, 555:129-138.
44. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry 1965, 122:509-522.
45. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annual Review of Neuroscience 1999, 22:197-217.
46. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Sanchez-Sellero I., Cruz-Landeira A., Lamas M.L. Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals: potential implications in relation to oxidative stress. Life Sciences 2001, 69:879-889.
47. Stein A.L., Alves D., da Rocha J.T., Nogueira C.W., Zeni G. Copper iodide-catalyzed cyclization of (Z)-chalcogenoenynes. Organic Letters 2008, 10:4983-4986.
48. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
49. Taksande B.G., Kotagale N.R., Tripathi S.J., Ugale R.R., Chopde C.T. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 2009, 57:415-424.
50. Ursini F., Bindoli A. The role of selenium peroxidases in the protection against oxidative damage of membranes. Chemistry and Physics of Lipids 1987, 44:255-276.
51. Wilhelm E.A., Jesse C.R., Bortolatto C.F., Nogueira C.W., Savegnago L. Anticonvulsant and antioxidant effects of 3-alkynyl selenophene in 21-day-old rats on pilocarpine model of seizures. Brain Research Bulletin 2009, 79:281-287.
52. Wilhelm E.A., Jesse C.R., Roman S.S., Nogueira C.W., Savegnago L. Hepatoprotective effect of 3-alkynyl selenophene on acute liver injury induced by D-galactosamine and lipopolysaccharide. Experimental and Molecular Pathology 2009, 87:20-26.
53. 3H]5-hydroxytryptamine uptake in rat cortex. Brain Research 1996, 738:96-102.